Veridien Climate Action ETF CLIA
Set alert
As of Aug 16, 10:33 AM ET
- Open
- 18.58
- Prev close
- 18.61
- Mkt cap
- 25.40M
- Vol
- 75.56K
- Avg vol
- 36.44K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 18.55
- High
- 18.61
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 19.37
- 200-d avg
- 19.18
News
3 days ago globenewswire.com
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
- Agreement complements revenue from standard gene expression and DRP® services - Development and validation services will support a European biotechnology company's precision oncology predictive…
2 weeks ago gurufocus.com
ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology wi
2 weeks ago gurufocus.com
Natera's Signatera™ MRD Test Named to TIME's List of the Best Inventions of 2026
[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease
2 weeks ago gurufocus.com
bioAffinity Technologies to Present New Perspectives on CyPath® Lung's Use for Cancer Risk Assessment at CHEST 2026
[url="]bioAffinity Technologies, Inc.[/url] (Nasdaq: BIAF; BIAFW),a biotechnology company developing noninvasive healthcare solutions for the early detection an
2 weeks ago gurufocus.com
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
[url="]Natera, Inc.[/url] (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and [url="]TransCode Therapeutics, Inc[/url]. (Nasdaq: RNAZ),
2 weeks ago gurufocus.com
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
[url="]bioAffinity Technologies[/url], Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company developing noninvasive healthcare solutions for the early detection an
2 weeks ago accessnewswire.com
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx® Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers TAMPA, FL /…
3 weeks ago gurufocus.com
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
[url="]bioAffinity Technologies, Inc.[/url] (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection an
3 weeks ago gurufocus.com
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
[url="]bioAffinity Technologies[/url], Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company focused on the need for noninvasive tests for the detection of early-s
3 weeks ago gurufocus.com
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Soci
1 month ago gurufocus.com
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the I
2 months ago businesswire.com
Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics launched its in-house, high-complexity CLIA-certified laboratory in Iowa City, Iowa.
3 months ago globenewswire.com
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
Allarity Therapeutics is now poised to run its DRP ® testing in-house in a CLIA-certified laboratory environment The FDA requires that biomarker testing to select patients for registration trials…
4 months ago gurufocus.com
bioAffinity Technologies Announces Pricing of $3.2 Million Offering
[url="]bioAffinity Technologies, Inc.[/url] (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detectio
5 months ago gurufocus.com
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri Test Substantially Increased Cancer Detection With R
5 months ago gurufocus.com
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
5 months ago gurufocus.com
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology C
7 months ago seekingalpha.com
Lumos Diagnostics Holdings Limited (LDXHF) Discusses CLIA Waiver Clearance for FebriDx, Capital Raise, and Commercialization Strategy Transcript
Lumos Diagnostics Holdings Limited (LDXHF) Discusses CLIA Waiver Clearance for FebriDx, Capital Raise, and Commercialization Strategy Transcript
8 months ago globenewswire.com
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to conduct patient testing and develop companion diagnostics Laboratory provides significant operational…
2 years ago globenewswire.com
Veridien Climate Action ETF (CLIA) to Close
CHICAGO and MILWAUKEE and NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- The Board of Trustees of Tidal Trust II has decided to liquidate and close the Veridien Climate Action ETF (the “Fund”), based on…
-
2 years ago benzinga.com
ON Semiconductor Seals Multi-Year Deal with Volkswagen for Advanced EV Solutions; Stock Gains
ON Semi to provide power solutions for Volkswagen vehicles, utilizing EliteSiC M3e MOSFET-based power box and new silicon carbide plant.
-
2 years ago benzinga.com
STMicroelectronics Stock Gains After EV Deal With Geely Auto - What's Going On?
STMicroelectronics & Geely signed SiC supply deal for electric vehicles, also collaborating on solutions for automotive electronics & new energy vehicles.
-
2 years ago benzinga.com
Not All Chipmakers Are Doing Great; STMicroelectronics Lowers Annual Outlook After Q1 Performance
STM reported 18.4% revenue decline in Q1 2024, missed consensus estimates. Margins decreased and outlook for Q2 and 2024 is lower than expected.
-
2 years ago benzinga.com
STMicroelectronics Flips the Switch on Sustainability With Another Renewable Energy Agreement In Italy
STMicroelectronics signs 10-year PPA with Centrica for renewable energy supply in Italy starting Jan 2025, aims for carbon neutrality by 2027.